Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

Biotechnology

Healthcare
$16.99 +0.58%

+$0.04 today

Market cap
$3.10B
Beta
0.90
P/E (TTM)
98.7
EPS (TTM)
$0.07
52W Low $4.40High $10.08

Volume 2.76M

Average 1.66M

XERS Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Xeris Biopharma Holdings, Inc.NASDAQ: XERS

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue grows, but more slowly than its trailing trend

Q1 FY2026 revenue of $83.13M rose 38.3% year over year, behind the +41.5% change in trailing-twelve-month revenue. Sequentially, it fell 3.1% from the prior quarter. Over 3 fiscal years it compounded at +38.3% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 5 analysts of $401.51M (+37.6%) for the fiscal year ending Dec 2026, a slowdown from the +43.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$83.13M-3.1% QoQ
Last fiscal yearDec 2025
$291.85M+43.7% YoY
LTMMar 2026
$314.85M+41.5% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+38.3%+26.0%-12.3 pp
1 year+43.7%+37.6%-6.1 pp
3-year CAGR+38.3%+30.0%-8.3 pp
5-year CAGR+25.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
291.85M USD
Year-over-year change
+43.7%
4-year CAGR
+55.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How XERS compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +41.5% is the 4th highest of 7, against a peer median of +50.6%.
  • Over three fiscal years its annual growth of +38.3% compares with a peer median of +53.7%.
XERS Competitors
Revenue for XERS and competitors
Company Period LTM YoY 3-year CAGR
ASNDAscendis Pharma A/SLTM Sep 2026€1.21B EUR+86.9%+138.2%
CORTCorcept Therapeutics IncorporatedLTM Jun 2026$830.81M USD+16.0%+23.7%
MNKDMannKind CorporationLTM Mar 2026$360.78M USD+21.2%+51.8%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$314.85M USD+41.5%+38.3%
SEPNSepterna, Inc.LTM Sep 2026$96.27M USD+336.7%—
ETONEton Pharmaceuticals, Inc.LTM Mar 2026$86.93M USD+79.9%+55.5%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$0 USD——
GHRSGH Research PLCLTM Mar 2026$0 USD——
SPRBSpruce Biosciences, Inc.LTM Mar 2026$0 USD-100.0%—
Peer median (excluding XERS) —+50.6%+53.7%

Competitors are the stored peer set for XERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue49.59M110.25M163.91M203.07M291.85M
Cost of Revenue13.32M22.63M28.65M36.83M53.41M
Gross Profit36.27M87.61M135.27M166.24M238.43M
Gross Margin73.1%79.5%82.5%81.9%81.7%
Research & Development25.16M20.97M22.34M25.56M31.17M
Selling, General & Admin125.72M137.75M146.1M163.48M182.37M
Operating Expenses151.43M169.55M179.28M199.88M213.54M
Depreciation & Amortization1.88M12.67M13.16M12.63M12.16M
EBITDA(113.67M)(69.31M)(23.74M)(13.99M)12.71M
EBITDA Margin-229.2%-62.9%-14.5%-6.9%4.4%
Operating Income(115.16M)(81.94M)(44.01M)(33.65M)24.9M
Operating Margin-232.2%-74.3%-26.8%-16.6%8.5%
Interest Income313K2.58M4.75M5.32M4.74M
Interest Expense7.18M14.1M26.61M33.18M29.08M
Other Income / Expenses(7.57M)(14.14M)(19.49M)(23.46M)(24.34M)
Income Before Tax(122.73M)(96.08M)(63.5M)(57.1M)554K
Pre-Tax Margin-247.5%-87.2%-38.7%-28.1%0.2%
Income Tax Expense0(1.42M)(1.25M)(2.27M)0
Net Income(122.73M)(94.66M)(62.26M)(54.84M)554K
Net Margin-247.5%-85.9%-38.0%-27.0%0.2%
EPS (Basic)(1.55)(0.70)(0.45)(0.37)0.00
EPS (Diluted)(1.55)(0.70)(0.45)(0.37)0.00
Weighted Avg Shares79.03M135.63M137.67M146.77M160.43M
Weighted Avg Shares (Diluted)79.03M135.63M137.67M146.77M172.74M

Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

Intrinsic Alpha fair value

Locked

Current Price

$16.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.